CEP295NL: A Potential Drug Target and Biomarker (G100653515)

Target Name: CEP295NL

NCBI ID: G100653515

CEP295NL

CEP295NL: A Potential Drug Target and Biomarker

The search for new drug targets and biomarkers has become a major focus in the pharmaceutical industry in recent years. These targets are essential for the development of new treatments for various diseases, including cancer. One potential drug target that is being explored is CEP295NL, a protein that is expressed in various tissues and cell types in the body.

CEP295NL is a cell surface glycoprotein that is characterized by its high expression in the liver, pancreas, and other tissues. It is composed of four chains, including a N-terminal alpha chain, a middle chain, a T-terminal beta chain, and a C-terminal gamma chain. The CEP295NL protein is involved in various physiological processes in the body, including cell signaling, inflammation, and metabolism.

One of the key functions of CEP295NL is its role in the immune system. CEP295NL has been shown to play a critical role in the regulation of immune cell function, specifically in the T cell lineage. CEP295NL has been shown to interact with the protein PD-L1, which is a negative regulator of T cell activation. This interaction between CEP295NL and PD-L1 has been shown to promote the development of T cell malignancy.

In addition to its role in the immune system, CEP295NL has also been shown to be involved in various signaling pathways in the body. For example, CEP295NL has been shown to be involved in the PI3K/Akt signaling pathway, which is a critical pathway involved in cell signaling and metabolism.

The potential drug target for CEP295NL is based on its involvement in the immune system and its potential to promote the development of T cell malignancy. Drugs that target CEP295NL have the potential to treat various diseases, including T cell malignancies, autoimmune diseases, and metabolic disorders.

In conclusion, CEP295NL is a protein that is being explored as a potential drug target and biomarker. Its role in the immune system and its potential to promote the development of T cell malignancy make it an attractive target for new therapies. Further research is needed to fully understand the mechanisms of CEP295NL and its potential as a drug target.

Protein Name: CEP295 N-terminal Like

The "CEP295NL Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CEP295NL comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets